Comparative Pharmacology
Head-to-head clinical analysis: BROMPHERIL versus CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHERIL versus CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY.
BROMPHERIL vs CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brompheril is a mu-opioid receptor agonist with additional sigma-1 receptor antagonism, producing analgesic effects and modulating neuropathic pain.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
In adults, the usual dose is 1-2 mg/kg intravenously every 4-6 hours as needed. Alternatively, 5 mg can be administered intramuscularly or subcutaneously every 4 hours.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
None Documented
None Documented
Terminal half-life 2.5-4 hours; prolonged in renal impairment (up to 12 hours in severe cases).
14.4 hours (range 11-16 hours) in healthy adults; prolonged in renal impairment.
Primarily renal (60-70% as unchanged drug); 15-20% fecal via biliary elimination; minor metabolic clearance.
Primarily fecal (80%) and renal (11%) as unchanged drug.
Category C
Category A/B
Antihistamine
Antihistamine